XML 62 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue (Tables)
 12 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset, Contract Liability, and Receivable
The following table summarizes our contract balances:
September 30,
(in thousands) 20242023
Contract assets(1)
$2,031 $2,816 
Contract liabilities(2)
2,131 2,999 
(1) consists of unbilled amounts primarily related to Biopharma contracts which consists of research and development agreements with third parties.
(2) Generally results from receipt of advance payment before our performance related to Biopharma contracts.
Summary of Revenue by Geographic Region
The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia and Australia.

Year ended September 30,
(in thousands)202420232022
Americas$193,884 $151,263 $122,473 
EMEA92,567 71,389 62,078 
APAC26,523 22,457 19,014 
Total$312,974 $245,109 $203,565 
Summary of Revenue by Product
The table below sets forth revenues by products.
Year ended September 30,
(in thousands)202420232022
Synthetic genes$92,679 $73,541 $61,509 
Oligo pools16,906 14,489 12,424 
DNA libraries13,933 10,201 6,149 
Antibody discovery20,328 23,172 24,171 
NGS tools169,128 123,706 99,312 
Total$312,974 $245,109 $203,565 
Summary of Revenue by Industry
The table below sets forth revenues by industry.

Year ended September 30,
(in thousands)202420232022
Industrial chemicals/materials$83,472 $59,321 $57,940 
Academic research58,452 45,847 37,097 
Healthcare168,959 137,148 106,363 
Food/agriculture2,091 2,793 2,165 
Total revenues$312,974 $245,109 $203,565